Warning lights
Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.
-
Busy address KBO
11 other companies have their registered office at the same address; threshold 10.
-
Not on Peppol Peppol
Not registered in the Peppol network, mandatory for VAT-liable companies since 1 January 2026.
Financials
Financial year 2025
BASF PHARMA BELGIUM from Antwerpen, company number BE0845445466, closed financial year 2025 with a result of € 183,245 after tax. Compared with financial year 2024, the result moved from € 337,113 to € 183,245. The company is profitable. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on May 28, 2026.
€ 11.6 million
▲ 2% vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ 183,245
▼ 46% vs 2024
Profit after tax over the fiscal year.
Stays in the company
No dividend for 2025. Retained profit grew to € -36.4 million.
Debts at end 2025
None
No bank loans on the last day of the fiscal year.
€ 19,198
▼ 20% vs 2024
Supplier invoices still open on the last day of the fiscal year. Pays suppliers within 105 days on average.
Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Profit after taxes | € -17,302 | € 296,443 | € 337,113 | € 183,245 | ▼ 46% |
| Equity | € 10,811,399 | € 11,107,843 | € 11,444,955 | € 11,628,201 | ▲ 2% |
| Total debts | € 7,774 | € 9,522 | € 24,107 | € 19,198 | ▼ 20% |
| Retained profit | € -37,188,601 | € -36,892,157 | € -36,555,045 | € -36,371,799 | ▲ € 183,245 |
| Balance sheet total | € 10,819,173 | € 11,117,364 | € 11,469,062 | € 11,647,398 | ▲ 2% |
Key figures of BASF PHARMA BELGIUM, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to BASF PHARMA BELGIUM?
What happened at BASF PHARMA BELGIUM in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- Jan Remeysen stepped down as director. NBB
- New annual accounts for financial year 2025: profit of € 183,245 (▼ 46% vs 2024). Source: NBB ↗
- Bart Goossens stepped down as director. NBB
- Bart Goossens became a director. NBB
- Stefanie Demming stepped down as director. NBB
- Jan Remeysen became a director. NBB
- Stefanie Demming became a director. NBB
- New establishment in Antwerpen. KBO
In short
From € 17,302 loss in 2022 to € 183,245 profit in 2025.
Best year ever: 2024, with € 337,113 profit.
Pays suppliers within 105 days on average.
A new publication or filing at BASF PHARMA BELGIUM? We notify you, reason included.
Follow BASF PHARMA BELGIUMDatabakkes Pro
Know what changes at your customers, suppliers and competitors. Without reading an annual account.
- Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
- We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
- In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.
Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.
De Lijn 8 June 2026 New annual account 2025
filed on 8 June 2026
What was left
€ 20 k ▼ 91%
Money in the bank
€ 178 k ▼ 98%
Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit
Management
The shares are held by BASF Antwerpen NV (100%) and BASF Belgium Coordination Center Comm.V (0%). It owns 100% of BASF Pharma (Callanish) Ltd. itself.
Directors
According to the 2025 annual accounts
Jan Remeysen
Director
Also active at: VLAAMS ECONOMISCH VERBOND, Vlaams Netwerk van Ondernemingen, ACTA, BASF BELGIUM COORDINATION CENTER, ANTWERP MANAGEMENT SCHOOL
since 2025 · until 2028
since 2026 · until 2026
Stefanie Demming
Director
since 2025 · until 2026
Shareholders
Participations
BASF Pharma (Callanish) Ltd.
100%
Establishments
Establishment units
Physical locations of this company
Scheldelaan 600
2040 Antwerpen
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 11 companies are registered at this address.
All companies at this address →BASF Antwerpen same network
€ 5.7 billion revenue · 2025
BASF Personeelsclub
BASF Werknemers en Tariefbedienden
BASF VOORZORGSFONDS
BASF Kaderleden en Directie
+6 more
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0845.445.466
- VAT number
- BE 0845.445.466
- Registered office
- Scheldelaan 600, 2040 Antwerpen
- Names & denominations
- BASF PHARMA BELGIUM
- Enterprise type
- Rechtspersoon
- Legal form
- Public limited company
- Legal situation
- Normale toestand
- Start date
- 23 April 2012
- Peppol
- Not registered